61
METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENTAL DISORDERS. March 15, 2018: US20180073076-A1

This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.


62
Targeting GIV-GEF-GI Signaling for Treating Diverse Diseases. April 19, 2018: US20180104307-A1

The invention provides cell-permeable Ga-Interacting Vesicle associated protein (GIV)-derived peptides and their use for treatment of diverse diseases. The invention further provides C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT)-based peptides and GIV-CT encoding vectors and metho ...


63
EXTENDED RELEASE TABLET OF CYCLOBENZAPRINE. May 3, 2018: US20180116967-A1

A directly compressed extended release cyclobenzaprine tablet and method for making the tablet that includes homogenously mixing: (i) cyclobenzaprine, (ii) a filler selected from the group consisting of lactose, spray-dried lactose, mannitol, and combinations thereof; and (iii) a glidant selected fr ...


64
Biosensor Tattoos and Uses Therefor for Biomarker Monitoring. May 3, 2018: US20180119077-A1

Provided herein are devices and methods used to produce tattoo biosensors that are based on spatially controlled intracutaneous gene delivery of optical reporters driven by specific transcription factor pathways for a given cytokine or other analyte. The biosensors can be specific to a given analyte ...


65
MUTATIONS OF THE PIK3CA GENE IN HUMAN CANCERS. May 3, 2018: US20180119231-A1

Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the c ...


66
PRODUCT BASED ON IRON BIS-GLYCINATE CHELATE AND ALGINIC ACID AND/OR WATER-SOLUBLE SALTS THEREOF, FORMULATIONS THEREOF, AND PHARMACEUTICAL USES THEREOF. May 24, 2018: US20180140570-A1

The object of the present invention is a product obtainable by spray-drying an aqueous solution comprising iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, preferably sodium alginate, potassium alginate and/or magnesium alginate, the use of said product for the prevent ...


67
INDUCTION OF PANCREATIC BETA CELLS BY STEM CELL DIFFERENTIATION WITH RNA. May 17, 2018: US20180135021-A1

A novel method of inducing or producing pancreatic beta cells from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent t ...


68
INDUCTION OF HEPATOCYTES BY STEM CELL DIFFERENTIATION WITH RNA. May 17, 2018: US20180135023-A1

A novel method of inducing or producing hepatocytes from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent to mesendod ...


69
ADMINISTRATION REGIMEN FOR THERAPEUTIC AGENTS FOR ATAXIA IN SPINOCEREBELLAR DEGENERATION. KISSEI PHARMACEUTICAL, May 31, 2018: US20180147189-A1

The present invention is directed to provide excellent pharmaceutical compositions for the treatment of ataxia in spinocerebellar degeneration with which the risk of side effects caused by elevation of thyroid hormone levels is reduced. The present invention relates to a pharmaceutical composition f ...


70
BIOMARKERS FOR PREDICTING A RESPONSE TO AN IMMUNOMODULATING TREATMENT IN PATIENTS WITH INFLAMMATORY DISEASE. August 2, 2018: US20180217159-A1

The present invention provides a method and a kit for predicting the response to an immunomodulatory treatment in patients that present an inflammatory disease such as multiple sclerosis, which are based on the quantification of the plasma levels ratio of cytokines IL-17F, IFN-γ and IL-10 in a biolo ...